Royce & Associates’s Neurogene NGNE Stock Holding History

Royce & Associates’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,270	Closed	-$93K	–	944
2022 Q3	$93K	Hold	7,270	–	–	﹤0.01%	903
2022 Q2	$150K	Hold	7,270	–	–	﹤0.01%	913
2022 Q1	$273K	Hold	7,270	–	–	﹤0.01%	929
2021 Q4	$701K	Hold	7,270	–	–	0.01%	849
2021 Q3	$1.05M	Hold	7,270	–	–	0.01%	812
2021 Q2	$1.34M	Hold	7,270	–	–	0.01%	816
2021 Q1	$1.79M	Hold	7,270	–	–	0.01%	767
2020 Q4	$2.05M	Hold	7,270	–	–	0.02%	722
2020 Q3	$1.75M	Hold	7,270	–	–	0.02%	703
2020 Q2	$2.41M	Hold	7,270	–	–	0.03%	630
2020 Q1	$1.66M	Hold	7,270	–	–	0.02%	639
2019 Q4	$1.79M	Hold	7,270	–	–	0.02%	721
2019 Q3	$414K	Hold	7,270	–	–	﹤0.01%	917
2019 Q2	$343K	Hold	7,270	–	–	﹤0.01%	944
2019 Q1	$392K	Hold	7,270	–	–	﹤0.01%	938
2018 Q4	$314K	Hold	7,270	–	–	﹤0.01%	958
2018 Q3	$426K	Hold	7,270	–	–	﹤0.01%	987
2018 Q2	$385K	Hold	7,270	–	–	﹤0.01%	1027
2018 Q1	$2.05M	Hold	7,270	–	–	0.01%	843
2017 Q4	$1.71M	Hold	7,270	–	–	0.01%	874
2017 Q3	$2.06M	Hold	7,270	–	–	0.01%	830
2017 Q2	$2.05M	Hold	7,270	–	–	0.01%	836
2017 Q1	$2.43M	Sell	7,270 -705	-9%	-$248K	0.02%	804
2016 Q4	$2.63M	Sell	7,975 -156	-2%	-$41.9K	0.02%	748
2016 Q3	$2.17M	Sell	8,131 -1,000	-11%	-$202K	0.01%	784
2016 Q2	$1.21M	Buy	9,131 +4,323	+90%	+$687K	0.01%	888
2016 Q1	$848K	Buy	4,808 +3,877	+416%	+$754K	0.01%	946
2015 Q4	$232K	Hold	931	–	–	﹤0.01%	1068
2015 Q3	$262K	Sell	931 -4,712	-84%	-$1.09M	﹤0.01%	1093
2015 Q2	$783K	Hold	5,643	–	–	﹤0.01%	1047
2015 Q1	$968K	Sell	5,643 -880	-13%	-$179K	﹤0.01%	1023
2014 Q4	$978K	Buy	6,523 +2,336	+56%	+$333K	﹤0.01%	1078
2014 Q3	$558K	Buy	+4,187	New	+$639K	﹤0.01%	1199

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royce & Associates's NGNE Position: Q4 2022 in Review

Royce & Associates sold out of Neurogene (NGNE) in Q4 2022, closing a stake of 7,270 shares — an estimated $93K sold.

Royce & Associates first reported a position in NGNE in Q3 2014 and held it in 33 quarters. The position peaked at $2.63M in Q4 2016. 45 funds tracked by Wall St. Rank hold NGNE as of Q4 2022.

Royce & Associates reported no remaining Neurogene position as of Q4 2022 after selling out during the quarter.
Royce & Associates sold 7,270 Neurogene shares in Q4 2022, an estimated $93K.
Royce & Associates first reported a position in Neurogene in Q3 2014 and held it in 33 quarters.
Royce & Associates's Neurogene position peaked at $2.63M in Q4 2016.
45 funds tracked by Wall St. Rank held Neurogene as of Q4 2022.

Based on Royce & Associates's 13F filing for Q4 2022, filed 13 Feb 2023.